CVPR Drugs Flashcards
Group 1 Antiarrhythmics
- Sodium channel blockers
- local anesthetics that prolong the QRS duration
- divided into Groups 1A, 1B, 1C
Group 1A - Procainamide, quinidine, disopyramide, amiodarone
- prolong the action potential
- reduce phase 0 and 4 sodium currents
- reduce phase 3 potassium current
Group 1B - lidocaine, mexiletine, phenytoin
- most selective, have significant effects on sodium channels in depressed ischemic tissue
- no effect of atrial tissue
- phenytoin can be used to reduce digitalis-induced arrhythmias
Group 1C - Flecainide
- no effect on ventricular AP duration or QT interval
- powerful depressants of sodium current, slow conduction velocity in atrial and ventricular cells
- increase QRS duration
Group 2 - Beta Blockers
- Propanolol, esmolol, metoprolol, timolol
- cardiac beta adrenoreceptor blockade and reduction in cAMP
- AV node is sensitive to these and PR interval is prolonged
Group 3 - Dofetilide, ibutilide, sotalol, amiodarone
- potassium blockers
- prolong action potential duration caused by blockade of Ik channels
- increase QT interval
Group 4 - Calcium L-type Channel Blockers
- Verapamil, diltiazem
- cause selective depression of calcium current, decrease AV conduction velocity, PR interval and refractory period is increased
Adenosine
- when given in high doses as IV bolus, the drug slows or completely blocks conduction in the AV node by hyper-polarizing, and reducing calcium current
- found naturally in body, low toxicity
- short duration of action
Potassium ion
- depresses ectopic pacemakers, caused by digitalis toxicity
- hypokalemia=increased arrhythmia incidence
Magnesium ion
- Mg appears to have similar depressant effects as potassium
- also effective in some cases of torsades de pointes arrhythmia
Albuterol, terbutaline, metaproterenol
- short acting B2 agonist
- treat acute bronchospasm
- last 3-4 hours
- SE: hypokalemia, cardiac tachycardia, tachyphylaxis, hypoxaemia, NVD
Salmeterol, Formoterol
- long acting Beta2 agonist
- use for moderate/severe persistent asthma
- lasts 12 hours
- SE: hypokalemia, cardiac tachycardia, tachyphylaxis, NVD
Iprtropium bromide
- inhalation treatment for COPD
- muscarinic antagonist
- inhibits bronchoconstriction, tracheobronchial secretions
- use for asthma pts intolerant to B-agonists
- SE: dry mouth, palpitations, constipation, blurry vision, hallucinations, tachycardia, issues with glaucoma
Zarfirlukast, montelukast
- leukotriene receptor antagonist
- inhibits CYP3A4 and CYP2C9 increased warfarin 1/2 life
- mild/ moderate asthma
- SE: eosinophilia, hepatotoxicity, infections
Ziluteon
- inhibits 5-lipooxygenase
- inhibits CYP3A4 and can influence metabolism of terfenadine, warfarin, theophylline
- mild/moderate asthma
- SE: hepatotoxicity
Theophylline
- bronchodilator
- blocks PDE, inhibits breakdown of cAMP and activity of adenosine receptors on bronchial smooth muscle cells
- relieving and controller drug
- SE: cortical arousal, stimulates secretion of gastric acid and digestive enzyme, hypokalemia, hyperglycemia, tachycardia
Roflumilast
- PDE type 4 inhibitor
- for severe COPD, controller drug
- SE: tachycardia, not with pregnancy, depression, muscle spasm, avoid with CYP3A4 inhibitors
Methylprednisone, fluicasone, mometasone
- corticosteroids
- reduces bronchial reactivity, increases airway caliber
- increases beta 2 receptors
- inhibit cytokine production
- SE: glucose intolerance, immunosuppressive, weight gain, increase by, throat thrush, oral hoarseness
Cromolyn sodium
- only prophylactically
- inhibit antigen and exercise induced asthma
- no effect on airway smooth muscle tone
- inhibits calcium influx into mast cells caused by cross linking of IgE on cell surface
- Se: throat irritation, cough, bronchospasm, mouth dryness
Omalizumab
- Anti IgE, inhibits binding of IgE to mast cells
- long term reduces serum levels of free IgE
- reduces magnitude of early and late bronchospasm
- SE: anaphylaxis,
Epoprostenol, treprostinil, remodulin
- prostanoids
- PGI2 inhibits platelet activation and vasodilates
- dosing never changes even if weight does
Treprostinil, selexipag
- oral prostacyclins
- antiplatelet and vasodilatory actions
Bosentan, Ambrisentan, Macitentan
-ET1 levels are increased in PAH, these block ET1 receptor
Sildenafil, Tadalafil
-PDE5 inhibitor - blocks the degradation action of PDE5 on cyclic GMP in smooth muscle cells resulting in vasodilation of the vessels